Back to Trials
NCT04997096NARecruiting

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

Dana-Farber Cancer Institute

Start Date

4/2/2022

Completion Date

4/30/2029

Summary

The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).

Detailed Description

This research study is a randomized controlled trial that will compare an exercise group to a control group on lower extremity function, CIPN, and inflammatory markers in ovarian or endometrial cancer patients undergoing first-line chemotherapy after surgery. The names of the study interventions involved in this study are/is: * Aerobic and resistance exercise; virtually supervised 16-week aerobic and resistance exercise performed at home via Zoom * Attention control for 16 weeks, home-based stretching The research study procedures include: screening for eligibility and study interventions including evaluations and follow up visits. It is expected that about 30 people will take part in this research study.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Newly diagnosed patients with stages III-IV ovarian or endometrial cancer * Receiving first-line carboplatin and paclitaxel chemotherapy after surgery * ≥18 years, children under the age of 18 will be excluded due to rarity of disease * Physician's clearance to participate in moderate-vigorous intensity exercise * Able to read, write, and understand English * Ability to understand and the willingness to sign an informed consent document * Willing to undergo two venous blood draws for the study Exclusion Criteria: * Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist * Participants with uncontrolled intercurrent illness, as determined by the treating oncologist * Participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating oncologist * Participants who have received prior chemotherapy for cancer treatment (e.g. taxanes for breast cancer)

Interventions

OTHER

Exercise

OTHER

Attention Control

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Ovarian CancerOvarian CarcinomaOvarian Cancer Stage IVOvarian Cancer Stage IIIOvarian Cancer Stage 3Endometrial CancerEndometrial Cancer Stage

Locations

Dana Farber Cancer Institute

Boston, Massachusetts 02215

United States